Granulomatosis with polyangiitis and intravenous immunoglobulins: A case series and review of the literature

Autoimmunity Reviews

Volumn 14, Issue 8, 2015, Pages 659-664

  Guidelli, Giacomo Maria ^a   Tenti, Sara ^a   Pascarelli, Nicola Antonio ^a   Galeazzi, Mauro ^a   Fioravanti, Antonella ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

ANCA vasculitis; Granulomatosis with polyangiitis; Intravenous immunoglobulins

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; IMMUNOGLOBULINS, INTRAVENOUS;

ADULT; CLINICAL ARTICLE; COLOSTOMY; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMICOLECTOMY; HUMAN; IMMUNOFLUORESCENCE; LUNG ASPERGILLOSIS; LUNG LAVAGE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; REMISSION; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; WEGENER GRANULOMATOSIS; AGED; CASE REPORT; DRUG THERAPY, COMBINATION; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOLOGY; RECURRENCE; REMISSION INDUCTION;

ADULT; AGED; DRUG THERAPY, COMBINATION; FEMALE; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION;

EID: 84930752589     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.03.005     Document Type: Review

References (59)

1. Scott D.G., Watts R.A. Systemic vasculitis: epidemiology, classification and environmental factors. Ann Rheum Dis 2000, 59:161-163.
2. Falk R.J., Gross W.L., Guillevin L., Hoffman G.S., Jayne D.R., Jennette J.C., et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011, 63:863-864.
3. Lane S.E., Watts R., Scott D.G. Epidemiology of systemic vasculitis. Curr. Rheumatol Rep 2005, 7:270-275.
4. Mohammad A.J., Jacobsson L.T., Westman K.W., Sturfelt G., Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford) 2009, 48:1560-1565.
5. Fries J.F., Hunder G.G., Bloch D.A., Michel B.A., Arend W.P., Calabrese L.H., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990, 33:1135-1136.
6. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013, 65:1-11.
7. Merkel P.A., Lo G.H., Holbrook J.T., Tibbs A.K., Allen N.B., Davis J.C., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) study. Ann Intern Med 2005, 142:620-626.
8. Commarmond C., Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev 2014, 13:1121-1125.
9. Radice A., Bianchi L., Sinico R.A. Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. Autoimmun Rev 2013, 12:487-495.
10. Mukhtyar C., Guillevin L., Cid M.C., Dasgupta B., de Groot K., Gross W., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009, 68:310-317.
11. Hellmich B., Flossmann O., Gross W.L., Bacon P., Cohen-Tervaert J.W., Guillevin L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66:605-617.
12. Jayne D.R., Chapel H., Adu D., Misbah S., O'Donoghue D., Scott D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000, 93:433-439.
13. Martinez V., Cohen P., Pagnoux C., Vinzio S., Mahr A., Mouthon L., et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic antibodies. Arthritis Rheum 2008, 58:308-317.
14. Jayne D.R., Lockwood C.M. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996, 35:1150-1153.
15. Jayne D.R., Esnault V.L., Lockwood C.M. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun 1993, 6:207-219.
16. Richter C., Schnabel A., Csernok E., De Groot K., Reinhold-Keller E., Gross W.L. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995, 101:2-7.
17. Lapraik C., Watts R., Bacon P., Carruthers D., Chakravarty K., D'Cruz D., et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford) 2007, 46:1615-1616.
18. Luqmani R.A., Bacon P.A., Moots R.J., Janssen B.A., Pall A., Emery P., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87:671-678.
19. Merkel P.A., Seo P., Aries P., Neogi T., Villa-Forte A., Boers M., et al. Vasculitis Clinical Research Consortium; OMERACT 7 Special Interest Group. Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. J Rheumatol 2005, 32:2488-2495.
20. Jayne D., Rasmussen N., Andrassy K., Bacon P., Tervaert J.W., Dadoniené J., et al. European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003, 349:36-44.
21. Miescher S.M., Kasermann F. The future of immunoglobulin therapy: an overview of the 2nd international workshop on natural antibodies in health and disease. Autoimmun Rev 2013, 12:639-642.
22. Lockwood C.M. New treatment strategies for systemic vasculitis: the role of intravenous immunoglobulin therapy. Clin Exp Immunol 1996, 104:77-82.
23. Vaitla P.M., McDermott E.M. The role of high-dose intravenous immunoglobulin in rheumatology. Rheumatology (Oxford) 2010, 49:1040-1048.
24. Sherer Y., Levy Y., Fabrizzi F., Shoenfeld Y. Immunomodulation of various autoimmune diseases by intravenous immunoglobulin. Drugs Today (Barc) 1999, 35:513-518.
25. Sherer Y., Levy Y., Shoenfeld Y. Intravenous immunoglobulin (IVIG) therapy in autoimmune disease-SLE, antiphospholipid syndrome, vasculitis. What is New? 1999, 1-5. [http://www.rheuma21st.com/archives/cutting_edge_immunoglobulin.html (16.09.99)].
26. Rauova L., Rovensky J., Shoenfeld Y. Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins. Springer Semin Immunopathol 2001, 23:447-457.
27. Shoenfeld Y., Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005, 38:123-137.
28. Levy Y., Sherer Y., George J., Langevitz P., Ahmed A., Bar-Dayan Y., et al. Serologic and clinical response to treatment of systemic vasculitis and associated autoimmune disease with intravenous immunoglobulin. Int Arch Allergy Immunol 1999, 119:231-238.
29. Fortin P.M., Tejani A.M., Bassett K., Musini V.M. Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev 2013, 1:CD007057.
30. Croft A.P., Smith S.W., Carr S., Youssouf S., Salama A.D., Burns A., et al. Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis. Kidney Int 2014, [Epub ahead of print].
31. Abtahi S.M., Omrani M., Karimifar M., Eshaghian A., Kachuei M., Momeni A. Wegener's granulomatosis and mucoromycosis: a case study and review of literature. Adv Biomed Res 2012, 1:23.
32. Wiwatwongwana D., Esdaile J.M., White V.A., Dolman P.J. Intravenous immunoglobulin (IVIG) for orbital Wegener's granulomatosis. Can J Ophthalmol 2012, 47:82-83.
33. Alfhaily F., Watts R., Leather A. Wegener's granulomatosis occurring de novo during pregnancy. Clin Exp Rheumatol 2009, 27:S86-S88.
34. Kim S.Y., Linton J.M., Kolasinski S.L. Successful treatment of new onset Wegener's granulomatosis with IVIG (intravenous immunoglobulin) during pregnancy: a case report. Mod Rheumatol 2008, 18:177-180.
35. Arlet J.B., Le Thi Huong D, Marinho A., Cluzel P., Wechsler B., Piette J.C. Arterial aneurysms in Wegener's granulomatosis: case report and literature review. Semin Arthritis Rheum 2008, 37:265-268.
36. Aries P.M., Ullrich S., Gross W.L. A case of destructive Wegener's granulomatosis complicated by cytomegalovirus infection. Nat Clin Pract Rheumatol 2006, 2:511-515.
37. Ozbalkan Z., Kiraz S., Ozturk M.A., Ertenli A.I., Apras S., Calguneri M. Wegener's granulomatosis: clinical and laboratory results of a university hospital study of 20 patients from Turkey. Clin Rheumatol 2006, 25:358-363.
38. Bellisai F., Morozzi G., Marcolongo R., Galeazzi M. Pregnancy in Wegener's granulomatosis: successful treatment with intravenous immunoglobulin. Clin Rheumatol 2004, 23:533-535.
39. Ulinski T., Martin H., Mac Gregor B., Dardelin R., Cochat P. Fatal neurologic involvement in pediatric Wegener's granulomatosis. Pediatr Neurol 2005, 32:278-281.
40. Masterson R., Pellicano R., Bleasel K., McMahon L.P. Wegener's granulomatosis in pregnancy: a novel approach to management. Am J Kidney Dis 2004, 44:e68-e72.
41. Kamali S., Cefle A., Sayarlioglu M., Gul A., Inanc M., Ocal L., et al. Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases. Rheumatol Int 2005, 25:211-214.
42. Delèvaux I., André M., Aumaître O. Wegener's granulomatosis associated with common variable immunodeficiency. J Rheumatol 2002, 29:1577-1578.
43. Reinhold-Keller E., Beuge N., Latza U., de Groot K., Rudert H., Nölle B., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032.
44. Taylor C.T., Buring S.M., Taylor K.H. Treatment of Wegener's granulomatosis with immune globulin: CNS involvement in an adolescent female. Ann Pharmacother 1999, 33:1055-1059.
45. Adlakha A., Rao K., Adlakha K., Ryu J.H. A case of pediatric Wegener's granulomatosis with recurrent venous thromboses treated with intravenous immunoglobulin and laryngotracheoplasty. Pediatr Pulmonol 1995, 20:265-268.
46. Chakravarty K., Scott D.G., Blyth J., Courteney-Harris R.G. Wegener's granulomatosis in the elderly-unusual presentations and misdiagnosis. J Rheumatol 1994, 21:1157-1159.
47. Finkel T.H., Török T.J., Ferguson P.J., Durigon E.L., Zaki S.R., Leung D.Y., et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent?. Lancet 1994, 343:1255-1258.
48. Richter C., Schnabel A., Csernok E., Reinhold-Keller E., Gross W.L. Treatment of Wegener's granulomatosis with intravenous immunoglobulin. Adv Exp Med Biol 1993, 336:487-489.
49. Kamali S., Kasapoglu E., Aktürk F., Gül A., Inanc M., Ocal L., et al. Eosinophilia and hyperimmunoglobulinemia E as the presenting manifestations of Wegener's granulomatosis. Clin Rheumatol 2003, 22:333-335.
50. Lamprecht P., Voswinkel J., Lilienthal T., Nolle B., Heller M., Gross W.L., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002, 41:1303-1307.
51. Blum M., Andrassy K., Adler D., Hartmann M., Völcker H.E. Early experience with intravenous immunoglobulin treatment in Wegener's granulomatosis with ocular involvement. Graefes Arch Clin Exp Ophthalmol 1997, 235:599-602.
52. Gelfand E.W. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012, 367:2015-2025.
53. Tenti S., Guidelli G.M., Bellisai F., Galeazzi M., Fioravanti A. Long-term treatment of antiphospholipid syndrome with intravenous immunoglobulin in addition to conventional therapy. Clin Exp Rheumatol 2013, 31:877-882.
54. Rossi F., Jayne D.R., Lockwood C.M., Kazatchkine M.D. Anti-idiotypes against anti-neutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin Exp Immunol 1991, 83:298-303.
55. Shoenfeld Y., Gershwin M.E. Intravenous immunoglobulin new indications and mechanisms of action. Clin Rev Allergy Immunol 2005, 29:165-166.
56. Svetlicky N., Blank M., Zandman-Goddard G. The beneficial effects of intravenous immunoglobulin for antineutrophil cytoplasmic antibody-positive vasculitis. Isr Med Assoc J 2012, 14:568-569.
57. Orbach H., Katz U., Sherer Y., Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005, 29:173-184.
58. Zandman-Goddard G., Krauthammer A., Shoenfeld Y. The steroid-sparing effect of intravenous immunoglobulin in patients with autoimmune diseases. Expert Rev Clin Immunol 2007, 3:773-780.
59. Seite J.F., Shoenfeld Y., Youinou P., Hillion S. What is the contents of the magic draft IVIg?. Autoimmun Rev 2008, 7:435-439.